Diseases /
Acute Myeloid Leukemia
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification). [1]
Acute myeloid leukemias most frequently harbor alterations in DNMT3A, FLT3, TP53, NPM1, and RUNX1 [2].
DNMT3A Mutation, FLT3 Mutation, NPM1fs, TP53 Mutation, and TP53 Missense are the most common alterations in acute myeloid leukemia [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for acute myeloid leukemia, 5 are FDA-approved in at least one setting and 5 have NCCN guidelines in at least one setting [3].
Enasidenib +
Disease is predicted to be sensitive: -
Gemtuzumab Ozogamicin +
Disease is predicted to be sensitive: -
Gilteritinib +
Disease is predicted to be sensitive: -
Ivosidenib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): First Line of Therapy (FDA), Refractory (FDA, NCCN), Relapse (FDA, NCCN) |
| Note: Approved for adult patients with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. |
Midostaurin +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Consolidation Therapy (FDA, NCCN), Treatment Induction (FDA, NCCN) |
| Note: FDA-approved, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation, for adults with newly diagnosed, FLT3-mutated AML. |
Sorafenib +
Disease is predicted to be sensitive: -
Clinical Trials
There are 741 clinical trials for acute myeloid leukemia, of which 506 are open and 235 are completed or closed. Of the trials that contain acute myeloid leukemia as an inclusion criterion, 12 are early phase 1 (9 open), 269 are phase 1 (181 open), 160 are phase 1/phase 2 (114 open), 216 are phase 2 (146 open), 9 are phase 2/phase 3 (7 open), 54 are phase 3 (40 open), 2 are phase 4 (1 open), and 19 are no phase specified (8 open).
PML-RARA, FLT3, and t(15;17)(q22;q12) are the most frequent gene inclusion criteria for acute myeloid leukemia clinical trials [3].
Fludarabine, cytarabine, and azacitidine are the most common interventions in acute myeloid leukemia clinical trials.
Significant Genes in Acute Myeloid Leukemia
ABL1 +
ABL1 is altered in 0.42% of acute myeloid leukemia patients [2].
ABL1 is an inclusion eligibility criterion in 118 clinical trials for acute myeloid leukemia, of which 68 are open and 50 are closed. Of the trials that contain ABL1 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 32 are phase 1 (15 open), 22 are phase 1/phase 2 (16 open), 48 are phase 2 (29 open), 3 are phase 2/phase 3 (2 open), 9 are phase 3 (5 open), and 2 are no phase specified (0 open) [3].
ABL2 +
ABL2 is altered in 0.36% of acute myeloid leukemia patients [2].
ABL2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain ABL2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
AFF1 +
AFF1 is altered in 0.19% of acute myeloid leukemia patients [2].
AFF1 is an inclusion eligibility criterion in 99 clinical trials for acute myeloid leukemia, of which 48 are open and 51 are closed. Of the trials that contain AFF1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 30 are phase 1 (12 open), 15 are phase 1/phase 2 (9 open), 39 are phase 2 (20 open), 2 are phase 2/phase 3 (2 open), 9 are phase 3 (5 open), and 3 are no phase specified (0 open) [3].
ARAF +
ARAF is altered in 0.17% of acute myeloid leukemia patients [2].
ARAF is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
ASXL1 +
ASXL1 is altered in 13.44% of acute myeloid leukemia patients [2].
ASXL1 is an inclusion eligibility criterion in 34 clinical trials for acute myeloid leukemia, of which 28 are open and 6 are closed. Of the trials that contain ASXL1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 9 are phase 1 (7 open), 4 are phase 1/phase 2 (4 open), 17 are phase 2 (15 open), 1 is phase 2/phase 3 (0 open), and 2 are phase 3 (1 open) [3].
ATM +
ATM is altered in 1.87% of acute myeloid leukemia patients [2].
ATM is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ATM status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
BCL2 +
BCL2 is altered in 0.09% of acute myeloid leukemia patients [2].
BCL2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].
BCL6 +
BCL6 is altered in 0.52% of acute myeloid leukemia patients [2].
BCL6 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (0 open) [3].
BCOR +
BCOR is altered in 6.18% of acute myeloid leukemia patients [2].
BCOR is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCOR status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
BCR +
BCR is altered in 0.35% of acute myeloid leukemia patients [2].
BCR is an inclusion eligibility criterion in 117 clinical trials for acute myeloid leukemia, of which 67 are open and 50 are closed. Of the trials that contain BCR status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 32 are phase 1 (15 open), 21 are phase 1/phase 2 (15 open), 48 are phase 2 (29 open), 3 are phase 2/phase 3 (2 open), 9 are phase 3 (5 open), and 2 are no phase specified (0 open) [3].
BIRC3 +
BIRC3 is altered in 0.21% of acute myeloid leukemia patients [2].
BIRC3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
BRAF +
BRAF is altered in 0.71% of acute myeloid leukemia patients [2].
BRAF is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
CBFA2T3 +
CBFA2T3 is altered in 0.55% of acute myeloid leukemia patients [2].
CBFA2T3 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 1 is open and 1 is closed. Of the trials that contain CBFA2T3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (0 open) [3].
CBFB +
CBFB is altered in 0.52% of acute myeloid leukemia patients [2].
CBFB is an inclusion eligibility criterion in 60 clinical trials for acute myeloid leukemia, of which 24 are open and 36 are closed. Of the trials that contain CBFB status and acute myeloid leukemia as inclusion criteria, 22 are phase 1 (5 open), 7 are phase 1/phase 2 (4 open), 16 are phase 2 (7 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (4 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [3].
CBL +
CBL is altered in 2.9% of acute myeloid leukemia patients [2].
CBL is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 3 are open and 1 is closed. Of the trials that contain CBL status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].
CEBPA +
CEBPA is altered in 5.09% of acute myeloid leukemia patients [2].
CEBPA is an inclusion eligibility criterion in 9 clinical trials for acute myeloid leukemia, of which 7 are open and 2 are closed. Of the trials that contain CEBPA status and acute myeloid leukemia as inclusion criteria, 5 are phase 2 (3 open), 2 are phase 2/phase 3 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [3].
CREBBP +
CREBBP is altered in 1.47% of acute myeloid leukemia patients [2].
CREBBP is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain CREBBP status and acute myeloid leukemia as inclusion criteria, 4 are phase 2 (4 open) [3].
CRKL +
CRKL is altered in 0.09% of acute myeloid leukemia patients [2].
CRKL is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
CRLF2 +
CRLF2 is altered in 0.18% of acute myeloid leukemia patients [2].
CRLF2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain CRLF2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
CSF3R +
CSF3R is altered in 1.19% of acute myeloid leukemia patients [2].
CSF3R is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains CSF3R status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
DEK +
DEK is an inclusion eligibility criterion in 103 clinical trials for acute myeloid leukemia, of which 60 are open and 43 are closed. Of the trials that contain DEK status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 29 are phase 1 (15 open), 17 are phase 1/phase 2 (12 open), 43 are phase 2 (26 open), 2 are phase 2/phase 3 (1 open), 9 are phase 3 (5 open), and 1 is no phase specified (0 open) [3].
DNMT3A +
DNMT3A is altered in 20.62% of acute myeloid leukemia patients [2].
DNMT3A is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 3 are open and 1 is closed. Of the trials that contain DNMT3A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [3].
ELL +
ELL is altered in 1.1% of acute myeloid leukemia patients [2].
ELL is an inclusion eligibility criterion in 87 clinical trials for acute myeloid leukemia, of which 39 are open and 48 are closed. Of the trials that contain ELL status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 28 are phase 1 (10 open), 14 are phase 1/phase 2 (8 open), 32 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 3 are no phase specified (0 open) [3].
EPOR +
EPOR is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain EPOR status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
ETV6 +
ETV6 is altered in 4.28% of acute myeloid leukemia patients [2].
ETV6 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain ETV6 status and acute myeloid leukemia as inclusion criteria, 4 are phase 2 (4 open) [3].
EZH2 +
EZH2 is altered in 3.38% of acute myeloid leukemia patients [2].
EZH2 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain EZH2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
FBXW7 +
FBXW7 is altered in 0.25% of acute myeloid leukemia patients [2].
FBXW7 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FBXW7 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
FGFR1 +
FGFR1 is altered in 0.26% of acute myeloid leukemia patients [2].
FGFR1 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain FGFR1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [3].
FGFR2 +
FGFR2 is altered in 0.19% of acute myeloid leukemia patients [2].
FGFR2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
FGFR3 +
FGFR3 is altered in 0.32% of acute myeloid leukemia patients [2].
FGFR3 is an inclusion eligibility criterion in 7 clinical trials for acute myeloid leukemia, of which 6 are open and 1 is closed. Of the trials that contain FGFR3 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].
FGFR4 +
FGFR4 is altered in 0.26% of acute myeloid leukemia patients [2].
FGFR4 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain FGFR4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
FLT1 +
FLT1 is altered in 0.43% of acute myeloid leukemia patients [2].
FLT1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
FLT3 +
FLT3 is altered in 15.68% of acute myeloid leukemia patients [2].
FLT3 is an inclusion eligibility criterion in 191 clinical trials for acute myeloid leukemia, of which 112 are open and 79 are closed. Of the trials that contain FLT3 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 44 are phase 1 (21 open), 44 are phase 1/phase 2 (31 open), 74 are phase 2 (42 open), 2 are phase 2/phase 3 (1 open), 21 are phase 3 (15 open), and 4 are no phase specified (1 open) [3].
Gilteritinib, midostaurin, and sorafenib have evidence of efficacy in patients with FLT3 mutation in acute myeloid leukemia [3].
GATA1 +
GATA1 is altered in 0.19% of acute myeloid leukemia patients [2].
GATA1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains GATA1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
GATA2 +
GATA2 is altered in 3.57% of acute myeloid leukemia patients [2].
GATA2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains GATA2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
GLIS2 +
GLIS2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
HIP1 +
HIP1 is altered in 0.37% of acute myeloid leukemia patients [2].
HIP1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain HIP1 status and acute myeloid leukemia as inclusion criteria, 3 are phase 2 (3 open) [3].
HOXA9 +
HOXA9 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
HRAS +
HRAS is altered in 0.42% of acute myeloid leukemia patients [2].
HRAS is an inclusion eligibility criterion in 8 clinical trials for acute myeloid leukemia, of which 6 are open and 2 are closed. Of the trials that contain HRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [3].
IDH1 +
IDH1 is altered in 7.58% of acute myeloid leukemia patients [2].
IDH1 is an inclusion eligibility criterion in 19 clinical trials for acute myeloid leukemia, of which 16 are open and 3 are closed. Of the trials that contain IDH1 status and acute myeloid leukemia as inclusion criteria, 6 are phase 1 (5 open), 7 are phase 1/phase 2 (6 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [3].
Ivosidenib has evidence of efficacy in patients with IDH1 mutation in acute myeloid leukemia [3].
IDH2 +
IDH2 is altered in 10.54% of acute myeloid leukemia patients [2].
IDH2 is an inclusion eligibility criterion in 20 clinical trials for acute myeloid leukemia, of which 19 are open and 1 is closed. Of the trials that contain IDH2 status and acute myeloid leukemia as inclusion criteria, 4 are phase 1 (4 open), 6 are phase 1/phase 2 (6 open), 9 are phase 2 (8 open), and 1 is phase 3 (1 open) [3].
Enasidenib has evidence of efficacy in patients with IDH2 mutation in acute myeloid leukemia [3].
IGH +
IGH is altered in 0.37% of acute myeloid leukemia patients [2].
IGH is an inclusion eligibility criterion in 7 clinical trials for acute myeloid leukemia, of which 5 are open and 2 are closed. Of the trials that contain IGH status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].
IKZF1 +
IKZF1 is altered in 1.64% of acute myeloid leukemia patients [2].
IKZF1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 status and acute myeloid leukemia as inclusion criteria, 3 are phase 2 (1 open) [3].
IL7R +
IL7R is altered in 0.1% of acute myeloid leukemia patients [2].
IL7R is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain IL7R status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
JAK1 +
JAK1 is altered in 0.75% of acute myeloid leukemia patients [2].
JAK1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain JAK1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
JAK2 +
JAK2 is altered in 3.97% of acute myeloid leukemia patients [2].
JAK2 is an inclusion eligibility criterion in 6 clinical trials for acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain JAK2 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
JAK3 +
JAK3 is altered in 0.36% of acute myeloid leukemia patients [2].
JAK3 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain JAK3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
KAT6A +
KAT6A is altered in 0.51% of acute myeloid leukemia patients [2].
KAT6A is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KAT6A status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
KDM5A +
KDM5A is altered in 0.21% of acute myeloid leukemia patients [2].
KDM5A is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
KIT +
KIT is altered in 2.0% of acute myeloid leukemia patients [2].
KIT is an inclusion eligibility criterion in 33 clinical trials for acute myeloid leukemia, of which 20 are open and 13 are closed. Of the trials that contain KIT status and acute myeloid leukemia as inclusion criteria, 10 are phase 1 (5 open), 5 are phase 1/phase 2 (4 open), 12 are phase 2 (7 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 1 is no phase specified (0 open) [3].
KMT2A +
KMT2A is altered in 2.49% of acute myeloid leukemia patients [2].
KMT2A is an inclusion eligibility criterion in 158 clinical trials for acute myeloid leukemia, of which 86 are open and 72 are closed. Of the trials that contain KMT2A status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 46 are phase 1 (20 open), 27 are phase 1/phase 2 (19 open), 61 are phase 2 (35 open), 5 are phase 2/phase 3 (4 open), 13 are phase 3 (7 open), and 4 are no phase specified (0 open) [3].
KRAS +
KRAS is altered in 4.45% of acute myeloid leukemia patients [2].
KRAS is an inclusion eligibility criterion in 13 clinical trials for acute myeloid leukemia, of which 8 are open and 5 are closed. Of the trials that contain KRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 4 are phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [3].
LYN +
LYN is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain LYN status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
MAF +
MAF is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain MAF status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
MAFB +
MAFB is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAFB status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
MAP2K1 +
MAP2K1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain MAP2K1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 2 (2 open) [3].
MAP2K2 +
MAP2K2 is altered in 0.1% of acute myeloid leukemia patients [2].
MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MAP2K4 +
MAP2K4 is altered in 0.17% of acute myeloid leukemia patients [2].
MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MAP3K1 +
MAP3K1 is altered in 0.6% of acute myeloid leukemia patients [2].
MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MAPK1 +
MAPK1 is altered in 0.17% of acute myeloid leukemia patients [2].
MAPK1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MDM2 +
MDM2 is altered in 0.17% of acute myeloid leukemia patients [2].
MDM2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MDM4 +
MDM4 is altered in 0.34% of acute myeloid leukemia patients [2].
MDM4 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
MECOM +
MECOM is altered in 1.36% of acute myeloid leukemia patients [2].
MECOM is an inclusion eligibility criterion in 174 clinical trials for acute myeloid leukemia, of which 118 are open and 56 are closed. Of the trials that contain MECOM status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 64 are phase 1 (44 open), 32 are phase 1/phase 2 (22 open), 61 are phase 2 (41 open), 3 are phase 2/phase 3 (2 open), 11 are phase 3 (8 open), and 1 is no phase specified (0 open) [3].
MLF1 +
MLF1 is an inclusion eligibility criterion in 84 clinical trials for acute myeloid leukemia, of which 62 are open and 22 are closed. Of the trials that contain MLF1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 39 are phase 1 (28 open), 16 are phase 1/phase 2 (12 open), 23 are phase 2 (18 open), 2 are phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [3].
MLLT1 +
MLLT1 is altered in 0.69% of acute myeloid leukemia patients [2].
MLLT1 is an inclusion eligibility criterion in 88 clinical trials for acute myeloid leukemia, of which 39 are open and 49 are closed. Of the trials that contain MLLT1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 28 are phase 1 (10 open), 14 are phase 1/phase 2 (8 open), 33 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 3 are no phase specified (0 open) [3].
MLLT10 +
MLLT10 is altered in 0.68% of acute myeloid leukemia patients [2].
MLLT10 is an inclusion eligibility criterion in 87 clinical trials for acute myeloid leukemia, of which 39 are open and 48 are closed. Of the trials that contain MLLT10 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 28 are phase 1 (10 open), 14 are phase 1/phase 2 (8 open), 32 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 3 are no phase specified (0 open) [3].
MLLT3 +
MLLT3 is altered in 1.04% of acute myeloid leukemia patients [2].
MLLT3 is an inclusion eligibility criterion in 112 clinical trials for acute myeloid leukemia, of which 55 are open and 57 are closed. Of the trials that contain MLLT3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 34 are phase 1 (14 open), 16 are phase 1/phase 2 (9 open), 44 are phase 2 (23 open), 4 are phase 2/phase 3 (3 open), 10 are phase 3 (6 open), and 3 are no phase specified (0 open) [3].
MLLT4 +
MLLT4 is altered in 0.73% of acute myeloid leukemia patients [2].
MLLT4 is an inclusion eligibility criterion in 89 clinical trials for acute myeloid leukemia, of which 40 are open and 49 are closed. Of the trials that contain MLLT4 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 28 are phase 1 (10 open), 15 are phase 1/phase 2 (9 open), 33 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 3 are no phase specified (0 open) [3].
MNX1 +
MNX1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MPL +
MPL is altered in 1.02% of acute myeloid leukemia patients [2].
MPL is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MPL status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MYC +
MYC is altered in 1.11% of acute myeloid leukemia patients [2].
MYC is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 1 is open and 2 are closed. Of the trials that contain MYC status and acute myeloid leukemia as inclusion criteria, 3 are phase 2 (1 open) [3].
MYD88 +
MYD88 is altered in 0.17% of acute myeloid leukemia patients [2].
MYD88 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains MYD88 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
MYH11 +
MYH11 is altered in 0.21% of acute myeloid leukemia patients [2].
MYH11 is an inclusion eligibility criterion in 60 clinical trials for acute myeloid leukemia, of which 24 are open and 36 are closed. Of the trials that contain MYH11 status and acute myeloid leukemia as inclusion criteria, 22 are phase 1 (5 open), 7 are phase 1/phase 2 (4 open), 16 are phase 2 (7 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (4 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [3].
NF1 +
NF1 is altered in 3.95% of acute myeloid leukemia patients [2].
NF1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain NF1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
NOTCH1 +
NOTCH1 is altered in 1.26% of acute myeloid leukemia patients [2].
NOTCH1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NOTCH1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
NPM1 +
NPM1 is altered in 14.42% of acute myeloid leukemia patients [2].
NPM1 is an inclusion eligibility criterion in 123 clinical trials for acute myeloid leukemia, of which 90 are open and 33 are closed. Of the trials that contain NPM1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 45 are phase 1 (32 open), 23 are phase 1/phase 2 (18 open), 42 are phase 2 (30 open), 4 are phase 2/phase 3 (3 open), 7 are phase 3 (6 open), and 1 is no phase specified (1 open) [3].
NRAS +
NRAS is altered in 9.76% of acute myeloid leukemia patients [2].
NRAS is an inclusion eligibility criterion in 12 clinical trials for acute myeloid leukemia, of which 7 are open and 5 are closed. Of the trials that contain NRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (1 open), 4 are phase 1/phase 2 (1 open), and 5 are phase 2 (4 open) [3].
NRIP3 +
NRIP3 is altered in 0.73% of acute myeloid leukemia patients [2].
NRIP3 is an inclusion eligibility criterion in 87 clinical trials for acute myeloid leukemia, of which 39 are open and 48 are closed. Of the trials that contain NRIP3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 28 are phase 1 (10 open), 14 are phase 1/phase 2 (8 open), 32 are phase 2 (15 open), 1 is phase 2/phase 3 (1 open), 8 are phase 3 (5 open), and 3 are no phase specified (0 open) [3].
NSD1 +
NSD1 is altered in 0.74% of acute myeloid leukemia patients [2].
NSD1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
NTRK1 +
NTRK1 is altered in 0.52% of acute myeloid leukemia patients [2].
NTRK1 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia, of which 4 are open and 0 are closed. Of the trials that contain NTRK1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
NTRK2 +
NTRK2 is altered in 0.09% of acute myeloid leukemia patients [2].
NTRK2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain NTRK2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
NTRK3 +
NTRK3 is altered in 0.26% of acute myeloid leukemia patients [2].
NTRK3 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain NTRK3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
NUMA1 +
NUMA1 is altered in 0.73% of acute myeloid leukemia patients [2].
NUMA1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUMA1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 3 (1 open) [3].
NUP214 +
NUP214 is an inclusion eligibility criterion in 103 clinical trials for acute myeloid leukemia, of which 60 are open and 43 are closed. Of the trials that contain NUP214 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 29 are phase 1 (15 open), 17 are phase 1/phase 2 (12 open), 43 are phase 2 (26 open), 2 are phase 2/phase 3 (1 open), 9 are phase 3 (5 open), and 1 is no phase specified (0 open) [3].
NUP98 +
NUP98 is altered in 0.35% of acute myeloid leukemia patients [2].
NUP98 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
PBX1 +
PBX1 is an inclusion eligibility criterion in 31 clinical trials for acute myeloid leukemia, of which 21 are open and 10 are closed. Of the trials that contain PBX1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 8 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 16 are phase 2 (11 open), and 2 are phase 3 (1 open) [3].
PDGFRA +
PDGFRA is altered in 0.31% of acute myeloid leukemia patients [2].
PDGFRA is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain PDGFRA status and acute myeloid leukemia as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [3].
PDGFRB +
PDGFRB is altered in 0.69% of acute myeloid leukemia patients [2].
PDGFRB is an inclusion eligibility criterion in 6 clinical trials for acute myeloid leukemia, of which 6 are open and 0 are closed. Of the trials that contain PDGFRB status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 5 are phase 2 (5 open) [3].
PDS5B +
PDS5B is altered in 0.26% of acute myeloid leukemia patients [2].
PDS5B is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PDS5B status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PHF6 +
PHF6 is altered in 3.48% of acute myeloid leukemia patients [2].
PHF6 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain PHF6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
PML +
PML is altered in 4.02% of acute myeloid leukemia patients [2].
PML is an inclusion eligibility criterion in 34 clinical trials for acute myeloid leukemia, of which 15 are open and 19 are closed. Of the trials that contain PML status and acute myeloid leukemia as inclusion criteria, 12 are phase 1 (5 open), 6 are phase 1/phase 2 (2 open), 7 are phase 2 (2 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 4 are no phase specified (2 open) [3].
PPM1D +
PPM1D is altered in 1.01% of acute myeloid leukemia patients [2].
PPM1D is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
PRDM16 +
PRDM16 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain PRDM16 status and acute myeloid leukemia as inclusion criteria, 3 are phase 2 (3 open) [3].
PTEN +
PTEN is altered in 0.24% of acute myeloid leukemia patients [2].
PTEN is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
PTPN11 +
PTPN11 is altered in 5.8% of acute myeloid leukemia patients [2].
PTPN11 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain PTPN11 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
RAD21 +
RAD21 is altered in 2.22% of acute myeloid leukemia patients [2].
RAD21 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RAD21 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
RAF1 +
RAF1 is altered in 0.09% of acute myeloid leukemia patients [2].
RAF1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
RARA +
RARA is altered in 1.37% of acute myeloid leukemia patients [2].
RARA is an inclusion eligibility criterion in 34 clinical trials for acute myeloid leukemia, of which 15 are open and 19 are closed. Of the trials that contain RARA status and acute myeloid leukemia as inclusion criteria, 12 are phase 1 (5 open), 6 are phase 1/phase 2 (2 open), 7 are phase 2 (2 open), 2 are phase 2/phase 3 (2 open), 3 are phase 3 (2 open), and 4 are no phase specified (2 open) [3].
RB1 +
RB1 is altered in 0.32% of acute myeloid leukemia patients [2].
RB1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RB1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
RET +
RET is altered in 0.33% of acute myeloid leukemia patients [2].
RET is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RET status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
RIT1 +
RIT1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
RPN1 +
RPN1 is an inclusion eligibility criterion in 173 clinical trials for acute myeloid leukemia, of which 117 are open and 56 are closed. Of the trials that contain RPN1 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 64 are phase 1 (44 open), 32 are phase 1/phase 2 (22 open), 60 are phase 2 (40 open), 3 are phase 2/phase 3 (2 open), 11 are phase 3 (8 open), and 1 is no phase specified (0 open) [3].
RUNX1 +
RUNX1 is altered in 14.8% of acute myeloid leukemia patients [2].
RUNX1 is an inclusion eligibility criterion in 100 clinical trials for acute myeloid leukemia, of which 57 are open and 43 are closed. Of the trials that contain RUNX1 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 30 are phase 1 (11 open), 14 are phase 1/phase 2 (11 open), 37 are phase 2 (25 open), 3 are phase 2/phase 3 (2 open), 9 are phase 3 (5 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [3].
RUNX1T1 +
RUNX1T1 is altered in 1.43% of acute myeloid leukemia patients [2].
RUNX1T1 is an inclusion eligibility criterion in 63 clinical trials for acute myeloid leukemia, of which 26 are open and 37 are closed. Of the trials that contain RUNX1T1 status and acute myeloid leukemia as inclusion criteria, 22 are phase 1 (5 open), 9 are phase 1/phase 2 (6 open), 17 are phase 2 (7 open), 2 are phase 2/phase 3 (2 open), 7 are phase 3 (4 open), 1 is phase 4 (1 open), and 5 are no phase specified (1 open) [3].
SF3B1 +
SF3B1 is altered in 4.01% of acute myeloid leukemia patients [2].
SF3B1 is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia, of which 5 are open and 0 are closed. Of the trials that contain SF3B1 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
SH2B3 +
SH2B3 is altered in 0.56% of acute myeloid leukemia patients [2].
SH2B3 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain SH2B3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
SMARCA4 +
SMARCA4 is altered in 0.52% of acute myeloid leukemia patients [2].
SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SMARCB1 +
SMARCB1 is altered in 0.13% of acute myeloid leukemia patients [2].
SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SMC1A +
SMC1A is altered in 0.68% of acute myeloid leukemia patients [2].
SMC1A is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMC1A status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SMC3 +
SMC3 is altered in 0.76% of acute myeloid leukemia patients [2].
SMC3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SMC3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].
SRC +
SRC is altered in 0.14% of acute myeloid leukemia patients [2].
SRC is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains SRC status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
SRSF2 +
SRSF2 is altered in 12.04% of acute myeloid leukemia patients [2].
SRSF2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain SRSF2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
STAG2 +
STAG2 is altered in 5.37% of acute myeloid leukemia patients [2].
STAG2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain STAG2 status and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [3].
STAT3 +
STAT3 is altered in 0.26% of acute myeloid leukemia patients [2].
STAT3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains STAT3 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].
TCF3 +
TCF3 is altered in 0.53% of acute myeloid leukemia patients [2].
TCF3 is an inclusion eligibility criterion in 31 clinical trials for acute myeloid leukemia, of which 21 are open and 10 are closed. Of the trials that contain TCF3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 8 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 16 are phase 2 (11 open), and 2 are phase 3 (1 open) [3].
TET2 +
TET2 is altered in 13.92% of acute myeloid leukemia patients [2].
TET2 is an inclusion eligibility criterion in 6 clinical trials for acute myeloid leukemia, of which 5 are open and 1 is closed. Of the trials that contain TET2 status and acute myeloid leukemia as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [3].
TP53 +
TP53 is altered in 14.93% of acute myeloid leukemia patients [2].
TP53 is an inclusion eligibility criterion in 113 clinical trials for acute myeloid leukemia, of which 71 are open and 42 are closed. Of the trials that contain TP53 status and acute myeloid leukemia as inclusion criteria, 2 are early phase 1 (1 open), 35 are phase 1 (19 open), 19 are phase 1/phase 2 (13 open), 46 are phase 2 (31 open), 2 are phase 2/phase 3 (1 open), 8 are phase 3 (6 open), and 1 is no phase specified (0 open) [3].
TRA +
TRA is altered in 0.55% of acute myeloid leukemia patients [2].
TRA is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRA status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRB +
TRB is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRB status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRD +
TRD is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRD status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TRG +
TRG is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TRG status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
TYK2 +
TYK2 is altered in 0.12% of acute myeloid leukemia patients [2].
TYK2 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain TYK2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
U2AF1 +
U2AF1 is altered in 5.69% of acute myeloid leukemia patients [2].
U2AF1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain U2AF1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
WHSC1 +
WHSC1 is altered in 0.1% of acute myeloid leukemia patients [2].
WHSC1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain WHSC1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
WT1 +
WT1 is altered in 5.59% of acute myeloid leukemia patients [2].
WT1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain WT1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].
ZRSR1 +
ZRSR1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains ZRSR1 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
ZRSR2 +
ZRSR2 is altered in 1.68% of acute myeloid leukemia patients [2].
ZRSR2 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia, of which 2 are open and 0 are closed. Of the trials that contain ZRSR2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
